文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Immunization against infection in BALB/c mice using a subunit-based DNA vaccine derived from TSA, LmSTI1, KMP11, and LACK predominant antigens.

作者信息

Salehi-Sangani Ghodratollah, Mohebali Mehdi, Jajarmi Vahid, Khamesipour Ali, Bandehpour Mojgan, Mahmoudi Mahmoud, Zahedi-Zavaram Hadi

机构信息

Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Department of Medical Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

出版信息

Iran J Basic Med Sci. 2019 Dec;22(12):1493-1501. doi: 10.22038/IJBMS.2019.14051.


DOI:10.22038/IJBMS.2019.14051
PMID:32133069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7043880/
Abstract

OBJECTIVES: To design a multivalent DNA vaccine encoding the most immunogenic regions of the antigens including TSA (Thiol-specific antioxidant protein), LmSTI1 ( stress-inducible protein1), LACK ( homologue of receptors for activated C Kinase), and KMP11 (kinetoplastid membrane protein-11) on BALB/c mice. MATERIALS AND METHODS: The chimeric construct was generated including the most immunogenic epitopes containing a combination of domains and oligopeptides of the aforementioned genes. The construct was cloned into pcDNA 3.1 plasmid and named "pleish-dom." Following intramuscular injection of mice, the capability of the vector pleish-dom alone and with pIL-12 (expressing murine IL-12) to raise protective cytokines and parasite burden was evaluated in the BALB/c mice as a susceptible animal model against . RESULTS: The immunized mice with pleish-dom/pIL-12 showed the highest and the lowest levels of interferon-gamma (IFN-γ) and interleukin-10 (IL-10), as well as the lowest leishmanin skin test (LST) reactions, were found through 8 weeks post-infection. CONCLUSION: Although the obtained DNA vaccine from the immunogenic chimeric protein of antigens was able to induce a high level of IFN-γ, it partially protected mice against L. major. However co-administration with pIL-12 led to shift immune response to Th1 phenotype, granuloma formation, and lowered parasite burden, and consequently distinct protection was found.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/3bdda007071a/IJBMS-22-1493-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/121e45a39651/IJBMS-22-1493-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/41829a8670fa/IJBMS-22-1493-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/e51ddf5f3798/IJBMS-22-1493-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/1c79466cc080/IJBMS-22-1493-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/bc101d38fffa/IJBMS-22-1493-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/35241cd292b7/IJBMS-22-1493-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/808e1730f387/IJBMS-22-1493-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/3bdda007071a/IJBMS-22-1493-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/121e45a39651/IJBMS-22-1493-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/41829a8670fa/IJBMS-22-1493-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/e51ddf5f3798/IJBMS-22-1493-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/1c79466cc080/IJBMS-22-1493-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/bc101d38fffa/IJBMS-22-1493-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/35241cd292b7/IJBMS-22-1493-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/808e1730f387/IJBMS-22-1493-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/7043880/3bdda007071a/IJBMS-22-1493-g008.jpg

相似文献

[1]
Immunization against infection in BALB/c mice using a subunit-based DNA vaccine derived from TSA, LmSTI1, KMP11, and LACK predominant antigens.

Iran J Basic Med Sci. 2019-12

[2]
Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.

Infect Immun. 2002-6

[3]
A lentiviral vaccine expressing KMP11-HASPB fusion protein increases immune response to Leishmania major in BALB/C.

Parasitol Res. 2018-7

[4]
Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice.

Parasit Vectors. 2020-8-12

[5]
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.

Infect Immun. 2002-8

[6]
DNA vaccination with a plasmid encoding LACK-TSA fusion against Leishmania major infection in BALB/c mice.

Malays J Pathol. 2017-12

[7]
A non-pathogenic Leishmania tarentolae vector based- HCV polytope DNA vaccine elicits potent and long lasting Th1 and CTL responses in BALB/c mice model.

Mol Immunol. 2019-5-1

[8]
Th1 Platform Immune Responses Against Leishmania major Induced by Thiol-Specific Antioxidant-Based DNA Vaccines.

Jundishapur J Microbiol. 2014-2

[9]
Enhancement of immune response induced by DNA vaccine cocktail expressing complete LACK and TSA genes against Leishmania major.

APMIS. 2012-9-18

[10]
Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.

Infect Immun. 2003-7

引用本文的文献

[1]
Expression and immunogenicity evaluation of a novel Lentiviral multi- epitope vaccine against Leishmania major in BALB/c mice.

Trop Dis Travel Med Vaccines. 2025-7-1

[2]
Immunomodulatory activity of Trypanosoma cruzi recombinant antigen combination TSA-1-C4 and Tc24-C4 induce activation of macrophages and CD8 T cells.

Parasitol Res. 2025-1-24

[3]
An update on recombinant vaccines against leishmaniasis.

Indian J Med Res. 2024

[4]
Vaccine Designing Technology against Leishmaniasis: Current Challenges and Implication.

Curr Drug Discov Technol. 2025

[5]
Immunogenicity and protective efficacy of tuzin protein as a vaccine candidate in -infected BALB/c mice.

Front Immunol. 2024-1-11

[6]
Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment.

Pharmaceutics. 2023-12-29

[7]
Amphotericin B-Loaded Extracellular Vesicles Derived from Enhancing Cutaneous Leishmaniasis Treatment through In Vitro and In Vivo Studies.

Iran J Parasitol. 2023

[8]
A New Strategy for Mapping Epitopes of LACK and PEPCK Proteins of Specific for Major Histocompatibility Complex Class I.

Int J Mol Sci. 2023-3-22

[9]
Bioinformatics analysis for the purpose of designing a novel multi-epitope DNA vaccine against Leishmania major.

Sci Rep. 2022-10-27

[10]
Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.

Vaccine. 2020-10-9

本文引用的文献

[1]
Cutaneous leishmaniasis: Distinct functions of dendritic cells and macrophages in the interaction of the host immune system with Leishmania major.

Int J Med Microbiol. 2017-11-6

[2]
Comparative Assessment of Induced Immune Responses Following Intramuscular Immunization with Fusion and Cocktail of LeIF, LACK and TSA Genes Against Cutaneous Leishmaniasis in BALB/c Mice.

Arch Immunol Ther Exp (Warsz). 2017-8-4

[3]
Wound healing in cutaneous leishmaniasis: A double edged sword of IL-10 and TGF-β.

Comp Immunol Microbiol Infect Dis. 2017-4

[4]
Modulation of the Immune Response to DNA Vaccine Encoding Gene of 8-kDa Subunit of Antigen B Using Murine Interleukin-12 Plasmid in BALB/c Mice.

Iran J Parasitol. 2016

[5]
Cutaneous leishmaniasis: immune responses in protection and pathogenesis.

Nat Rev Immunol. 2016-7-18

[6]
Pathways leading to interleukin-12 production and protective immunity in cutaneous leishmaniasis.

Cell Immunol. 2016-11

[7]
Leishmaniasis in high-burden countries: an epidemiological update based on data reported in 2014.

Wkly Epidemiol Rec. 2016-6-3

[8]
Field randomized trial to evaluate the efficacy of the Leish-Tec® vaccine against canine visceral leishmaniasis in an endemic area of Brazil.

Vaccine. 2016-4-27

[9]
Status of vaccine research and development of vaccines for leishmaniasis.

Vaccine. 2016-6-3

[10]
Intradermal Immunization of Leishmania donovani Centrin Knock-Out Parasites in Combination with Salivary Protein LJM19 from Sand Fly Vector Induces a Durable Protective Immune Response in Hamsters.

PLoS Negl Trop Dis. 2016-1-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索